Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Cefepime Hydrochloride | |
| Synonyms |
Cefepime Hydrochloride CEFEPIME HYDROCHLORIDE Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))- Maxipime |
|
| Definitions |
The hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1041 |
|
| Accepted_Therapeutic_Use_For |
Upper respiratory tract and urinary tract infections; febrile neutropenic conditions
|
|
| CAS_Registry |
123171-59-5
|
|
| CHEBI_ID |
CHEBI:31368
|
|
| Chemical_Formula |
C19H24N6O5S2.2ClH.H2O
|
|
| code |
C1041
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA
|
|
| DEFINITION |
The hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins.
|
|
| Display_Name |
Cefepime Hydrochloride
|
|
| FDA_UNII_Code |
I8X1O0607P
|
|
| FULL_SYN |
Cefepime Hydrochloride CEFEPIME HYDROCHLORIDE Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))- Maxipime
|
|
| Has_Free_Acid_Or_Base_Form | ||
| label |
Cefepime Hydrochloride
|
|
| Legacy Concept Name |
Cefepime
|
|
| NCI_Drug_Dictionary_ID |
38350
|
|
| PDQ_Closed_Trial_Search_ID |
38350
|
|
| PDQ_Open_Trial_Search_ID |
38350
|
|
| Preferred_Name |
Cefepime Hydrochloride
|
|
| prefixIRI |
Thesaurus:C1041
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance Antibiotic
|
|
| UMLS_CUI |
C0771284
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |